Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
The first project will focus on developing an AI-based platform for the sterically guided design of bispecific antibodies
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
Viatel bioresorbable polymers are increasingly used in dental and orthopedic implants
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
This facility represents a significant step in Croda’s Pharma business strategy to ‘Empower biologics delivery’
Subscribe To Our Newsletter & Stay Updated
_256_384.JPG)
